Medicine Design , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States.
Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States.
J Med Chem. 2018 May 24;61(10):4273-4282. doi: 10.1021/acs.jmedchem.7b00969. Epub 2017 Nov 17.
Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state. A half-life of 12-48 h is generally ideal for once daily dosing of oral drugs. If the half-life is too short, it may require more frequent dosing in order to maintain desired exposures and avoid unnecessarily high peak concentrations. This may pose challenges to achieving optimal efficacy, safety, and patient compliance. If the half-life is too long, the time over which accumulation and subsequent elimination occur may be prolonged. This may pose problems with managing adverse effects and the design of efficient clinical trials. Half-life is a key parameter for optimization in research and development. Structural modification to affect clearance, and to a lesser extent volume of distribution, is the preferred means of modulating half-life. An effective approach to half-life optimization requires an understanding of the many pitfalls associated with its estimation and interpretation.
药物半衰期对给药方案和稳态时的峰谷比有重要影响。半衰期为 12-48 小时通常是每日一次口服药物的理想选择。如果半衰期太短,则可能需要更频繁地给药,以维持所需的暴露量并避免不必要的高峰浓度。这可能会对实现最佳疗效、安全性和患者依从性构成挑战。如果半衰期太长,则积累和随后消除的时间可能会延长。这可能会导致不良反应的管理和高效临床试验的设计出现问题。半衰期是研究和开发中优化的关键参数。结构修饰以影响清除率,在较小程度上影响分布容积,是调节半衰期的首选方法。有效的半衰期优化方法需要了解与其估计和解释相关的许多陷阱。